AVITA Medical, Inc.RCEL
What AVITA Medical, Inc. does.
AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery.
Our current commercial portfolio includes RECELL ® (“RECELL”), and two complementary wound care products, PermeaDerm ® and Cohealyx ™ , which together support a comprehensive standard of care for acute wounds.
At the forefront of our portfolio is RECELL, approved by the United States Food & Drug Administration (the “FDA”) for the treatment of thermal burn wounds and full-thickness skin defects. While RECELL is also approved in the United States for restoring pigmentation of stable depigmented vitiligo lesions, we have paused further commercial investment in vitiligo at this time.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $34.4M | $50.1M | $64.3M | $71.6M |
| Net income | — | — | -$26.7M | -$35.4M | -$61.8M | -$48.6M |
| Free cash flow | — | — | -$19.5M | -$39.4M | -$58.1M | -$32.2M |
More on RCEL.
- AVITA Medical, Inc. summary
- AVITA Medical, Inc. financial statements
- AVITA Medical, Inc. key metrics
- AVITA Medical, Inc. health scores and style box
- AVITA Medical, Inc. earnings
- AVITA Medical, Inc. dividends
- AVITA Medical, Inc. valuation
- AVITA Medical, Inc. ownership and insiders
- AVITA Medical, Inc. peers
Figures from AVITA Medical, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.